Johnson & Johnson has announced its intention to invest over $2 billion to build a new biologics manufacturing facility in Wilson, North Carolina.

The new facility will expand capacity of biologic medicines covering areas including oncology, immunology, and neuroscience. Construction is expected to begin in the first half of 2025, and upon completion, the site will employ around 420 full-time employees.